Literature DB >> 25170541

The proapoptotic effect of formononetin in human osteosarcoma cells: involvement of inactivation of ERK and Akt pathways.

Yun Liu1, JinJie He, XiaoMing Chen, Jian Li, MaoRong Shen, WenJun Yu, Yuan Yang, ZengMing Xiao.   

Abstract

BACKGROUND: Previous studies have shown that some phytoestrogens inhibits proliferation and induces apoptosis in estrogen-dependent cancers via estrogen receptor (ER)-mediated signaling pathway. In view of the expression of ER in human osteosarcoma cells, the purpose of this study is to investigate whether formononetin and calycosin, two of the major isoflavones in Radix astragali, could also elicit anti-tumor activity against osteosarcoma, along with the underlying mechanism.
METHODS: Human osteosarcoma cells U2OS were respectively treated with various concentrations of formononetin or calycosin. Cell proliferation was determined by MTT assay, while apoptosis by flow cytometry. Next, the expression levels of apoptosis-related genes ERK, Akt, Bcl-2, Bax and caspase-3 were quantified by real-time PCR and Western blotting.
RESULTS: Formononetin exhibited higher anti-proliferative activities toward human osteosarcoma cells U2OS, when compared with calycosin. Therefore, U2OS cells were then respectively treated with various concentrations of formononetin, in order to elucidate the isoflavones-related signaling pathway. It was found that formononetin dose-dependently triggered apoptosis of U2OS cells in vitro. Furthermore, treatment of formononetin led to significant inactivation of ERK and Akt, followed by downregulation of Bcl-2, upregulation of Bax and finally increased expression of caspase-3.
CONCLUSION: Formononetin is more effective than calycosin at promoting cell death of U2OS cells by induction of apoptosis, which is mediated by inactivation of ERK and Akt signaling pathways. Thus isoflavones, especially formononetin, may be useful as anti-cancer drugs for osteosarcoma through their apoptosis-inducing effects.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25170541     DOI: 10.1159/000363029

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  14 in total

1.  Enhanced Wnt signaling by methylation-mediated loss of SFRP2 promotes osteosarcoma cell invasion.

Authors:  Qiang Xiao; Yu Yang; Xuepu Zhang; Qing An
Journal:  Tumour Biol       Date:  2015-12-01

2.  Suppressive effect of formononetin on platelet-derived growth factor-BB-stimulated proliferation and migration of vascular smooth muscle cells.

Authors:  Zhuo Chen; Suixin Liu; Ying Cai; Kangling Xie; Wenliang Zhang; Lei Dong; Yuan Liu; Fan Zheng; Yaoshan Dun; Ning Li
Journal:  Exp Ther Med       Date:  2016-07-13       Impact factor: 2.447

3.  Shikonin inhibits invasiveness of osteosarcoma through MMP13 suppression.

Authors:  Biyong Deng; Bing Qiu
Journal:  Tumour Biol       Date:  2015-06-24

4.  SHARPIN overexpression induces tumorigenesis in human prostate cancer LNCaP, DU145 and PC-3 cells via NF-κB/ERK/Akt signaling pathway.

Authors:  Jin Li; Yiming Lai; Yi Cao; Tao Du; Lexiang Zeng; Ganping Wang; Xianju Chen; Jieqing Chen; Yongsheng Yu; Simin Zhang; Yiming Zhang; Hai Huang; Zhenghui Guo
Journal:  Med Oncol       Date:  2015-01-01       Impact factor: 3.064

5.  Overexpression of miR-100 inhibits growth of osteosarcoma through FGFR3.

Authors:  Yunlong Bi; Yu Jing; Yang Cao
Journal:  Tumour Biol       Date:  2015-05-29

6.  Overexpression of miR-506 inhibits growth of osteosarcoma through Snail2.

Authors:  Zhongxiang Yu; Yuting Zhang; Ningyang Gao; Xiang Wang
Journal:  Am J Transl Res       Date:  2015-12-15       Impact factor: 4.060

Review 7.  Formononetin: A Review of Its Anticancer Potentials and Mechanisms.

Authors:  Kai-Ching Tay; Loh Teng-Hern Tan; Chim Kei Chan; Sok Lai Hong; Kok-Gan Chan; Wei Hsum Yap; Priyia Pusparajah; Learn-Han Lee; Bey-Hing Goh
Journal:  Front Pharmacol       Date:  2019-07-26       Impact factor: 5.810

8.  Suppression of A549 cell proliferation and metastasis by calycosin via inhibition of the PKC‑α/ERK1/2 pathway: An in vitro investigation.

Authors:  Xu-Dong Cheng; Jun-Fei Gu; Jia-Rui Yuan; Liang Feng; Xiao-Bin Jia
Journal:  Mol Med Rep       Date:  2015-10-15       Impact factor: 2.952

9.  Low concentration of formononetin promotes proliferation of estrogen receptor-positive cells through an ERα-miR-375-PTEN-ERK1/2-bcl-2 pathway.

Authors:  Yan-Hong Guo; Feng-Yan Tang; Yong Wang; Wen-Jun Huang; Jing Tian; Hui-Ling Lu; Min Xin; Jian Chen
Journal:  Oncotarget       Date:  2017-10-19

Review 10.  Focus on Formononetin: Anticancer Potential and Molecular Targets.

Authors:  Samantha Kah Ling Ong; Muthu K Shanmugam; Lu Fan; Sarah E Fraser; Frank Arfuso; Kwang Seok Ahn; Gautam Sethi; Anupam Bishayee
Journal:  Cancers (Basel)       Date:  2019-05-01       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.